FDAnews
www.fdanews.com/articles/96884-lux-granted-fast-track-designation-by-fda-for-lx211

Lux Granted Fast Track Designation by FDA for LX211

August 7, 2007

Lux Biosciences announced that the FDA has granted fast-track designation for LX211 for the treatment of uveitis, an autoimmune disease characterized by chronic inflammation of the eye. 

Lux Biosciences said it began enrolling patients in pivotal clinical trials for LX211 earlier this year.

The company is conducting three controlled, double-masked studies aimed at supporting the approval of that product as a treatment for uveitis, collectively designated the LUMINATE program.

The company said it expects enrollment for the LUMINATE trial program to be completed by early 2008 and, if successful, Lux plans to seek regulatory approval for LX211 in late 2008.